May 29, 2012

EDAP Showcases Innovative Devices at American Urology Annual Meeting

Ablatherm-HIFU receives best poster award

Unprecedented interest and attendance at EDAP's booth from U.S. urologists

LYON, France, May 29, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, showcased its Ablatherm® High Intensity Focused Ultrasound (HIFU) and its Sonolith i-move at the American Urological Association (AUA) 2012 Annual Meeting held May 19-23 in Atlanta, GA. A large number of U.S. urologists attended EDAP's booth and device demonstrations.

Marc Oczachowski, Chief Executive Officer of EDAP TMS, remarked, "We have been attending AUA for twenty years, and this year we experienced record attendance and exceptional enthusiasm from U.S. urologists at our booth. This year we estimate that approximately 80% of our booth traffic was from U.S. attendees, a major increase from prior years when about half of booth traffic was from outside the U.S. Most important, nearly all the U.S. doctors visiting our booth expressed clear interest in both our ESWL and HIFU device platforms."

Mr. Oczachowski continued, "U.S. urologists are aware of the recent U.S. installations of our Sonolith i-move and are receiving positive feedback from U.S. users. This demonstrates that, in addition to our sales and marketing program, we are poised to benefit from peer communication. Awareness levels are building for the U.S. FDA filing for Ablatherm-HIFU as it approaches submission later this year. Many urologists that visited our booth inquired about ways to be prepared and educated about Ablatherm-HIFU in order to be well positioned in advance of potential approval and launch. We are very pleased to see such strong momentum."

Marc Oczachowski concluded, "As an additional confirmation of the global and scientific acceptance of Ablatherm-HIFU for the treatment of localized prostate cancer, the poster presented by Dr. Sebastien Crouzet from Edouard Herriot University Hospital, Lyon, France, regarding the oncological outcomes from HIFU as a primary care treatment for prostate cancer in 1098 patients, received the best poster award for its session."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm®, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit *http://www.edap-tms.com*, and *http://www.hifu-planet.com*.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans, the conclusiveness of the results of and success of its Ablatherm-HIFU clinical trials and expectations regarding the IDE submission to and approval by the FDA of the Ablatherm-HIFU device. Such statements are based on management's current expectations and are subject to a number of uncertainties, including the uncertainties of the regulatory process, and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

CONTACT: Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

+33 4 72 15 31 72

bconfort@edap-tms.com

Investors:

Stephanie Carrington

The Ruth Group

646-536-7017

scarrington@theruthgroup.com

Source: EDAP TMS SA